Nereid Therapeutics will advance research by Clifford Brangwynne of Princeton University following its launch with a $50m series A round from Apple Tree Partners.

Nereid Therapeutics, a US-based developer of treatments for cancer and neurodegenerative diseases based on research at Princeton University, was launched this week by venture firm Apple Tree Partners with $50m in series A capital. Nereid will develop therapies targeting biomolecular condensates, a specialised subunit of the cell, using research by scientific founder Clifford Brangwynne, a…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.